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Manuscript 1 
 2 
Asthma is one of the most common, treatable, chronic respiratory conditions in the 3 
United States (US) and globally. Despite availability of effective treatment, the majority of 4 
pediatric and adult patients with persistent asthma have chronically uncontrolled symptoms 5 
(Center for Disease Control, 2016).  This is often attributed to patient-level factors such as lack 6 
of adherence to prescribed treatment and poor self-management.  However, increasing evidence 7 
indicates clinicians play a major role in national patterns of sub-optimal asthma management.  In 8 
particular, it has been shown that clinicians often do not assess and manage asthma 9 
appropriately, and that lack of effective medication management (i.e., adherence to prescribing 10 
guidelines) subsequently decreases patient adherence to controller medications (Akinbami et al., 11 
2019).   Thus, improving patient outcomes requires improving asthma management by healthcare 12 
providers, including increasing familiarity with best-practice guidelines.  Therefore, the purpose 13 
of this brief report is to (1) summarize key points of current guidelines for asthma management 14 
and (2) delineate important changes enacted by the recent 2020 Expert Panel Report-4 (EPR-4) 15 
updates. 16 
The National Asthma Education and Prevention Program (NAEPP) developed the first 17 
set of U.S. asthma management guidelines in 1991.  In 2007, the NAEPP Expert Panel Report-3 18 
(EPR-3) released a comprehensive set of guidelines that summarized research-to-date and 19 
provided detailed "best practice" guidelines for clinical asthma management (National Asthma 20 
Education and Prevention Program, 2007).  This included defining criteria for classification of 21 
asthma severity and control based on patterns of symptoms, medication use, exacerbation 22 
history, and spirometry, along with recommendations for selecting appropriate stepwise therapy 23 
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Abstract 
Despite availability of effective medications, the majority of pediatric and adult patients 
with persistent asthma have uncontrolled symptoms. This has been attributed to patient non-
adherence and poor self-management, but clinicians also contribute through inaccurate 
assessment of asthma and lack of familiarity with best practice guidelines for medication 
management.  Thus, improving patient outcomes will require improving clinical management by 
healthcare providers, including utilization of evidence-based practice guidelines.  In this report, 
we briefly summarize key points of the national guidelines for asthma management and delineate 
important changes enacted by 2020 Expert Panel Report-4 updates.  These include revised 
recommendations on the use of fractional exhaled nitric oxide testing (FeNO), indoor allergen 
mitigation, bronchial thermoplasty, adjunctive immunotherapy, and important modifications to 
medication management that are likely to have wide-spread impact on prescribing throughout the 
United States.  In particular, for all patients ages 5 and older taking Stepwise therapy levels 3-4, 
it is now recommend to use single maintenance and reliever therapy (SMART), whereas use of 
intermittent inhaled corticosteroids (ICS) administered at the same time as short-acting beta 
agonist (SABA) is recommended for Step 2 to reduce symptom burden, improve control, and 
minimize total ICS dose. 
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(i.e., systematic, incremental increases in controller medication doses) corresponding with the 24 
level of severity and control (National Heart Lung and Blood Institues, 2011).   25 
From 2007 to 2020, no further updates were published.  While the Global Initiative for 26 
Asthma (GINA) released annual updates reflecting a rapidly-evolving global science of asthma 27 
management, U.S. guidelines remained static (Global Initiative for Asthma, 2020). In December 28 
2020, the long-awaited EPR-4 released a number of selected updates to EPR-3 (National Heart 29 
Lung and Blood Institute, 2020).  These are summarized below, along with core 30 
recommendations that remain unchanged from EPR-3. 31 
Unchanged core recommendations for all ages include: 32 
(1) Classification of asthma severity quantitatively by frequency of daytime symptoms, 33 
nocturnal wakening, activity limitations, short-acting beta-agonist (SABA) use, 34 
exacerbations requiring oral corticosteroid (OCS) use, and FEV1%predicted; 35 
(2) Classification of asthma control by preceding criteria but utilizing different 36 
thresholds; 37 
(3) Use of stepwise therapy that corresponds with level of severity and control, with 38 
recommendation to seek expert help for all patients at Step 4 and above; 39 
(4) Treatment of non-life-threatening asthma exacerbations with one SABA treatment 40 
(range 2 to 6 puffs) every 20 minutes as needed based on severity, up to three times in 41 
one-hour prior to seeking emergency care, and consider short course of OCS; 42 
(5) Emphasis on self-management training to be provided at each asthma-related visit; 43 
and 44 
(6) Reevaluation of uncontrolled asthma every 2-6 weeks until controlled and every 3-6 45 
months thereafter. 46 
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 47 
EPR-4 changes to previous guidelines for management and treatment of asthma include 48 
modifications to several therapeutic areas (Cloutier et al., 2020).  49 
(1) Fractional exhaled nitric oxide testing (FeNO) should not be used to assess severity 50 
of asthma exacerbations or to determine treatment.  FeNO testing may be considered 51 
for the diagnosis of allergic asthma in conjunction with history and exam, particularly 52 
if spirometry results are unclear.  FeNO may also be used as part of an ongoing 53 
management plan that includes regular FeNO testing.   54 
(2) Indoor allergen mitigation (e.g., dust mite covers) is not routinely recommended, 55 
unless the patient has a history of atopic (allergic type) asthma.  For those with atopic 56 
asthma, a multimodal approach to allergen mitigation should be used to increase 57 
efficacy. 58 
(3) Bronchial thermoplasty (i.e., high heat directed at the bronchial walls to reduce 59 
hyperresponsiveness and bronchospasm), is no longer recommended based on 60 
procedural risk and limited evidence of efficacy. 61 
(4) Adjunctive subcutaneous immunotherapy (SCIT) may be used in patients with 62 
moderate persistent atopic asthma, but should be avoided in patients with severe 63 
asthma.  SCIT should not be administered during exacerbations due to increased risk 64 
of adverse events.  Use of sublingual immunotherapy is not recommended, based on 65 
limited evidence of efficacy.  66 
(5) Changes to first-line medication management of adults and children, will likely 67 
result in major shifts in prescribing practices across the United States.    68 
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These important changes to medication management can be briefly summarized as 69 
follows:  70 
(1) For children ages 0-4 years with recurrent wheezing, consider initiating a 7-10 day 71 
course of inhaled corticosteroids at onset of upper respiratory infection; 72 
(2) For Step 2 (mild persistent asthma), consider use of intermittent low-dose inhaled 73 
corticosteroids (ICS) for adults and children ages 5+ years;  74 
(3) For Steps 3 and 4 (moderate persistent asthma), use of low- to medium-dose Single 75 
Maintenance and Reliever Therapy (SMART) is strongly recommended as first-line 76 
treatment for patients ages 5 years and older;  77 
(4) For Step 5 (severe persistent asthma), in adults and children over 12 years, consider 78 
adding long-acting muscarinic agonist (LAMA) to daily ICS and LABA;   79 
(5) For patients with Type 2 allergic asthma, consider adjunct use of immunotherapy in 80 
patients with worsening symptoms following exposure to allergens. 81 
The introduction of SMART therapy and intermittent use of inhaled corticosteroids for 82 
mild asthma are the most significant prescribing changes that have occurred with EPR-4.  83 
SMART is the use of ICS together with formoterol (LABA) for both daily (controller) and as 84 
needed (rescue), instead of SABA alone.  Use of SMART has been shown to reduce 85 
exacerbation risk and improve asthma control and quality of life.  For this reason, SMART has 86 
been the preferred treatment globally for several years, however is only recently being integrated 87 
into US standards of care.  Similarly, intermittent use of ICS with LABA or SABA as needed for 88 
symptom relief in mild asthma has been shown to reduce total ICS exposure and improve 89 
symptom control, with equivalent or superior reduction in risk of acute exacerbation.  Based on 90 
these changes, for patients with mild to moderate persistent asthma, it is no longer recommended 91 
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to increase the daily dose of ICS during respiratory infection; those using SMART or as needed 92 
ICS will automatically receive additional ICS with increased rescue puffs. 93 
Currently, Formoterol is the only LABA that is recommended for use in this manner, as 94 
the evidence for these changes was derived from formoterol-based studies.  For children ages 5-95 
11 years, up to 8 total puffs of ICS with formoterol can be administered (36 mcg); for adults and 96 
children older than 12 years, up to 12 total daily puffs may be administered (54 mcg).  While 97 
SMART is now the recommended first-line treatment for Steps 3 and 4, it is actually off-label 98 
use, as these combination inhalers have not yet been FDA approved for use in this manner in the 99 
United States.  The lack of policy concordance poses problems for clinicians who might attempt 100 
to utilize SMART, as many insurers currently cover only a single-month supply of these 101 
expensive medications.  Thus, changes to insurance coverage will likely be needed to enable 102 
wide-spread access and adherence to this new evidence-based recommendation.  Additionally, 103 
individuals with inaccurate symptom perception may be poor candidates for as needed ICS. 104 
The changes implemented by EPR-4 correspond closely with current GINA guidelines, 105 
with the exception that GINA also advocates the intermittent use of  ICS with LABA for all 106 
individuals older than 12 years at both Step 1 and 2 (mild asthma) and generally discourages use 107 
of any SABA monotherapy in this population (Global Initiative for Asthma, 2020).  Thus, when 108 
managing teen and adult patients with asthma, nurse practitioners should consider prescribing 109 
low dose ICS, either intermittent or daily, based on level of symptoms. 110 
A few helpful rules can help to simplify understanding of stepwise therapy.  In general, 111 
for EPR3, EPR4, and GINA guidelines, use of low dose inhaled corticosteroids are 112 
recommended for Steps 1-3, medium dose for Steps 3-4, and high dose for Step 5-6, in both 113 
adults and children.  Furthermore, the addition of any LABA, LAMA, or LTRA to ICS therapy 114 
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generally increases the Stepwise therapy by one level.  For example, an adult patient taking 115 
Budesonide 180 mcg, one puff twice daily, with albuterol as needed (SABA) would be classified 116 
as Step 2 (low dose ICS), whereas use of the same low dose Budesonide plus formoterol 117 
(LABA) twice daily would be classified as Step 3 therapy.   118 
Prescribers should also be aware that ICS dosing is non-equivalent across different 119 
formulations (National Heart Lung and Blood Institues, 2011).  This point cannot be over-120 
emphasized, and mistakes in this area contribute substantially to prescribing errors.  For instance, 121 
an adult daily dose of fluticasone propionate 200 mcg (100 mcg given twice daily) is low-dose 122 
(Step 2), whereas fluticasone furoate 200 mcg (given once daily) is high-dose (Step 5).  For this 123 
reason, prescribers should utilize comparative dosing tables (see online e-supplement A) to 124 
ensure that appropriate doses of ICS are prescribed, consistent with best-practices.  Caution 125 
should be used when making insurance driven formulary changes, as evidence indicates that 126 
these changes might precede deterioration in lung function (Bickel, Nemer Eid, & Sayat, 2019). 127 
Lastly, minimum standards for asthma-related visits should include assessment and 128 
documentation of severity, control, stepwise therapy, and comparative ICS dosing (Box 1).  129 
Printable, clinician-friendly pocket-guides are included in the reference list for ages 5-11 years 130 
(Mammen, 2021b) and ages 12 years to adult (Mammen, 2021a) to facilitate accurate assessment 131 
and classification of asthma, and appropriate step-wise medication management. 132 
Conclusion.  Clinical management of asthma requires increasing precision in assessment 133 
and medication management.  Greater familiarity with asthma management guidelines will 134 
promote delivery of high-quality evidence-based care, and will help to improve patient outcomes 135 
and quality of life. 136 
 137 
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For all asthma related visits, assess and document: 
o Asthma severity 
o Asthma control (document all core criteria)* 
o Stepwise therapy level 
o Daily dose of ICS (intermittent, low, medium, high) 
o Self-management training provided 
o Follow up plan for uncontrolled asthma (2-6 weeks) 
Core criteria: *frequency of day time symptoms, nocturnal wakening due to asthma, activity limitations, SABA use, 
systemic corticosteroid use, and FEV1%predicted or Peak expiratory flow % of personal best if available. 
Box 1.  Checklist to promote clinician compliance with U.S. National guidelines for asthma care  
  
